1429386-05-9

Upstream product

• 5239-82-7 cyclopropylacetic acid 
• 1429385-25-0 2-chloro-N-((1R,2R)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-2-hydroxyethyl)acetamide 
• 1200828-74-5 ethyl α-bromocyclopropaneacetate 
• 1429385-24-9 (5R,6R)-6-(3-chlorophenyl)-5-(4-chlorophenyl)morpholin-3-one 
• 1429382-53-5 (1R,2R)-2-amino-1-(3-chlorophenyl)-2-(4-chlorophenyl)ethanol 

Relevant academic research and scientific papers

HETEROARYL ACID MORPHOLINONE COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).

HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.